Use of archived specimens in evaluation of prognostic and predictive biomarkers.

By Richard M. Simon, S. Paik, D. Hayes. Journal of the National Cancer Institute, 2009

1,041 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/8b64ce085a016f24807486fff9e085a05313f5a1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors (2011, result): “With our results, we reach level I evidence according to Simon and colleagues because our study consisted of 2 category B studies using archived samples from 2 similar but separate prospective clinical trials (16).”
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “Strict rules for incorporating prognostic or predictive markers into clinical practice have been published [134].”
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. (2014, background): “The evaluation of prognostic and predictive biomarkers is strengthened by the use of specimens from clinical trial participants [20].”
OncoKB: A Precision Oncology Knowledge Base (2017, background): “…annotation of germline variants 60,61 , efforts to define the clinical utility of somatic alterations have been limited to established biomarkers 62–64 and prior efforts have often classified actionability as a binary variable resulting in the grouping together of biomarkers that are…”
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2013, background): “does not require that the tests performed have been shown with a high level of evidence to have clinical utility.(138,139) Moreover, FDA”
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. (2018, background): “clinical utility have been proposed, either as prospective clinical trials(38,39) or as retrospective characterization of archived specimens from previous prospective clinical trials.(40) For ctDNA assays, the pre-analytical issues discussed above render the latter particularly problematic, unless c”
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016, background): “compared with treatment of the patient in the absence of the biomarker test result.(8,9,13) Benefits may include improvement in survival end points such as event-free survival, DFS, progressionfree survival, or OS.”
QIN “Radiomics: The Process and the Challenges” (2012, methodology): “Following the best practices in developing and then independently validating the observations in a distinct cohort is essential for reproducible results [92].”